Literature DB >> 21239180

Upregulation of TLR2 expression on G-CSF-mobilized peripheral blood stem cells is responsible for their rapid engraftment after allogeneic hematopoietic stem cell transplantation.

Young-Don Joo1, Won-Sik Lee, Hae-Jeong Won, Sun-Mi Lee, Jae-Hyeog Choi, Sang-Min Lee, Ki-Ho Han, Sae-Gwang Park, Il-Whan Choi, Su-Kil Seo.   

Abstract

Granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells (PBSCs) are more frequently used as the cellular source in allogeneic hematopoietic stem cell transplantation (HSCT) than bone marrow stem cells (BMSCs) because they promote more rapid engraftment and immune reconstitution. However, the underlying mechanism for this is not fully understood. Here, we investigated the role of Toll-like receptor 2 (TLR2) on PBSCs in promoting rapid engraftment after allogeneic HSCT. We found that PBSCs highly expressed TLR2 in comparison to BMSCs, and TLR2 was directly induced by G-CSF signaling. Treatment with the TLR2 ligand, Pam(3)CSK(4) (PAM), more efficiently induced myeloid differentiation of PBSCs than BMSCs. Similarly, endogenous TLR2 ligands from the serum of recipients of allogeneic transplantation more rapidly stimulated myeloid differentiation of PBSCs compared with BMSCs. PAM treatment of TLR2(-/-) syngeneic recipient mice transplanted with PBSCs resulted in significantly elevated numbers of PBSC-derived myeloid cells and spleen colony formation compared with controls. Our results demonstrate that TLR2 signaling in PBSCs correlates with their ability to rapidly differentiate into myeloid cells, resulting in improved engraftment. Thus, TLR2 may be a novel target for increasing the efficiency of allogeneic HSCT by overcoming engraftment failure or delayed engraftment.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21239180     DOI: 10.1016/j.cyto.2010.12.020

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  7 in total

1.  TLR2 agonism reverses chemotherapy-induced neutropenia in Macaca fascicularis.

Authors:  Nicholas J Laping; Michael P DeMartino; Joshua E Cottom; Jeffrey M Axten; John G Emery; Jeffrey H Guss; Miriam Burman; James J Foley; Mui Cheung; Allen Oliff; Sanjay Kumar
Journal:  Blood Adv       Date:  2017-12-08

2.  Staphylococcus aureus recognition by hematopoietic stem and progenitor cells via TLR2/MyD88/PGE2 stimulates granulopoiesis in wounds.

Authors:  Jennifer L Granick; Patrick C Falahee; Delsheen Dahmubed; Dori L Borjesson; Lloyd S Miller; Scott I Simon
Journal:  Blood       Date:  2013-07-18       Impact factor: 22.113

3.  Regulation of hematopoietic stem cell activity by inflammation.

Authors:  Laura G Schuettpelz; Daniel C Link
Journal:  Front Immunol       Date:  2013-07-19       Impact factor: 7.561

Review 4.  The Role of Toll-Like Receptors in Hematopoietic Malignancies.

Authors:  Darlene A Monlish; Sima T Bhatt; Laura G Schuettpelz
Journal:  Front Immunol       Date:  2016-09-28       Impact factor: 7.561

5.  Combination therapy of human umbilical cord blood cells and granulocyte colony stimulating factor reduces histopathological and motor impairments in an experimental model of chronic traumatic brain injury.

Authors:  Sandra A Acosta; Naoki Tajiri; Kazutaka Shinozuka; Hiroto Ishikawa; Paul R Sanberg; Juan Sanchez-Ramos; Shijie Song; Yuji Kaneko; Cesar V Borlongan
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

Review 6.  Danger Signals and Graft-versus-host Disease: Current Understanding and Future Perspectives.

Authors:  Tomomi Toubai; Nathan D Mathewson; John Magenau; Pavan Reddy
Journal:  Front Immunol       Date:  2016-11-29       Impact factor: 7.561

7.  Systemic TLR2 agonist exposure regulates hematopoietic stem cells via cell-autonomous and cell-non-autonomous mechanisms.

Authors:  A C Herman; D A Monlish; M P Romine; S T Bhatt; S Zippel; L G Schuettpelz
Journal:  Blood Cancer J       Date:  2016-06-17       Impact factor: 11.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.